These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 5968838)
21. Phospholine iodide (0.03 per cent) in the therapy of glaucoma. Atchoo PD; Vogel HP Am J Ophthalmol; 1966 Dec; 62(6):1044-8. PubMed ID: 5957878 [No Abstract] [Full Text] [Related]
23. [Echothiophate in the treatment of glaucoma]. Hirsch-Hoffmann AM Ophthalmologica; 1964; 147(2):96-102. PubMed ID: 5874637 [No Abstract] [Full Text] [Related]
24. Lens opacities in glaucoma patients on phospholine iodide therapy. De Roetth A Am J Ophthalmol; 1966 Oct; 62(4):619-28. PubMed ID: 5929123 [No Abstract] [Full Text] [Related]
25. The influence of position on intraocular pressure. Anderson DR; Grant WM Invest Ophthalmol; 1973 Mar; 12(3):204-12. PubMed ID: 4692261 [No Abstract] [Full Text] [Related]
26. Second round-table. Medical therapy of glaucoma. Doc Ophthalmol; 1972 Nov; 33(1):245-69. PubMed ID: 4637224 [No Abstract] [Full Text] [Related]
27. Effect of topically applied demecarium bromide and echothiophate iodide on intraocular pressure and pupil size in beagles with normotensive eyes and beagles with inherited glaucoma. Gum GG; Gelatt KN; Gelatt JK; Jones R Am J Vet Res; 1993 Feb; 54(2):287-93. PubMed ID: 8430939 [TBL] [Abstract][Full Text] [Related]
28. Glaucoma, miotic therapy and cataract. I. The frequency of anterior subcapsular vacuoles in glaucoma eyes treated with echothiophate (Phospholine Iodide), pilocarpine or pilocarpine-eserine, and in nonglaucomatous untreated eyes with common senile cataract. Axelsson U Acta Ophthalmol (Copenh); 1968; 46(1):83-98. PubMed ID: 5694669 [No Abstract] [Full Text] [Related]
32. Lens opacities in glaucoma patients on phospholine iodide therapy. De Roetth A Trans Ophthalmol Soc U K (1962); 1966; 86():89-100. PubMed ID: 5226620 [No Abstract] [Full Text] [Related]
33. [Echothiophate in glaucoma therapy]. Hirsch-Hoffmann AM Ophthalmologica; 1966; 152(4):291-3. PubMed ID: 5964206 [No Abstract] [Full Text] [Related]
35. [Long term results of 0,03 per cent phospholin iodide in serveral ocular hypertonia]. Corbel M; Leser C; François P; Razemon P Bull Soc Ophtalmol Fr; 1973 Mar; 73(3):455-60. PubMed ID: 4792544 [No Abstract] [Full Text] [Related]
36. The tonographic effects of echothiophate (phospholine) iodide: reversal by pyridine-2-aldoxine methiodide (P2AM). BECKER B; PYLE GC; DREWS RC Am J Ophthalmol; 1959 May; 47(5 Pt 1):635-40. PubMed ID: 13649819 [No Abstract] [Full Text] [Related]
37. Preliminary observations on the use of new concentrations of echothiophate iodide in the treatment of glaucoma. Kellerman L; King AD Am J Ophthalmol; 1966 Aug; 62(2):278-81. PubMed ID: 5944743 [No Abstract] [Full Text] [Related]
38. Echothiophate iodide induced transient hyper- and hypothyroidism. Mezer E; Krivoy N; Scharf J; Miller B J Glaucoma; 1996 Jun; 5(3):191-2. PubMed ID: 8795758 [TBL] [Abstract][Full Text] [Related]
39. [New drugs in glaucoma therapy]. Riegel D; Duzanéc Z; Knapp E Ber Zusammenkunft Dtsch Ophthalmol Ges; 1968; 68():358-9. PubMed ID: 5756797 [No Abstract] [Full Text] [Related]
40. Serum cholinesterase, serum lipase, and serum amylase levels during long-term echothiophate iodide therapy. Friberg TR; Thomas JV; Dressel TD Am J Ophthalmol; 1981 Apr; 91(4):530-3. PubMed ID: 6164295 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]